TB-500 Legal Status, FDA 503A Category, and Compounding Access
The present-tense facts, read straight from FDA: Category 2, not FDA-approved, WADA-prohibited — and an individually-named slot on the July 2026 PCAC agenda that means access is under active review.
TB-500 legal status: the present-tense FDA facts
TB-500 legal status, on the current record, has a clear present-tense reading — and a forward-leaning one worth stating up top. The momentum first: access is under active FDA review and may expand in 2026. FDA's Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23–24, 2026, and "TB-500 (free base)" and "TB-500 acetate" appear individually on its published agenda as bulk drug substances "being considered for inclusion on the 503A Bulks List" — the same agenda that lists BPC-157, KPV, and MOTs-C [16]. That is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status [16].
Now the fact that stands today. FDA lists this substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that TB-500 is the LKKTETQ fragment of thymosin beta-4 — and placed it in 503A "Category 2" (bulk substances that may present significant safety risks), effective with FDA's September 29, 2023 nominated-substances update, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information [17]. As a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding, and it is not an FDA-approved drug [17].
Those two readings are not in tension. A substance can be in Category 2 today and on a PCAC agenda for evaluation tomorrow — being discussed by PCAC is a step in evaluation, not a final listing decision [18]. The honest line is the one this whole site is built to hold: the present status is Category 2; the future is genuinely under review; and no reclassification has occurred, been dated, or been made certain.
What the 503A / 503B framework means here
Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [18].
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet on a bulks list are evaluated by FDA through a public nomination process, with input from PCAC [18].
FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation; Category 2 substances are those FDA identified as raising significant safety risks, and they are not afforded that discretion — FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [18]. On January 7, 2025, FDA finalized a revised interim policy under which it does not place newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated [18][19]. TB-500's Category 2 placement is the last FDA action confirmable from FDA.gov, so it is the status stated here.
How legally compounded peptide access works
Legally compounded access in the U.S. follows one pathway, and it begins with a clinician, not a catalog. A patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [20].
Telehealth is one front-end channel for the prescriber-evaluation step. It is a route to a licensed-prescriber consultation and prescription, not a separate legal status — it does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [20].
The ingredient-eligibility caveat is the load-bearing one for TB-500. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [20]. TB-500 is currently a Category 2 substance [17] — so while that status holds, it is not eligible for routine 503A compounding, regardless of the channel a prescription comes through. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.
The regulatory and anti-doping status flags
Is TB-500 FDA Approved?
No. TB-500 has no FDA-approved therapeutic indication, and it is not an FDA-approved drug [17]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding — and on both questions the answer for TB-500 is no approval and Category 2 standing [18]. FDA placed the LKKTETQ fragment in Category 2 citing potential immunogenicity for certain routes and a lack of important safety information [17].
Is TB-500 banned by WADA and in competitive sports?
Yes. TB-500 and thymosin beta-4 fall under prohibited peptide, growth-factor, and tissue-repair categories on the World Anti-Doping Agency Prohibited List, banned both in and out of competition for the relevant classes. They are detected by LC-MS anti-doping assays, and TB-500 has been encountered as a designer drug in racehorses, prompting equine and human detection methods. In some jurisdictions, such as Australia and New Zealand, it is classified as a prescription medicine.
The two flags reinforce the same read: a substance with no approved human indication, a Category 2 compounding status, and a place on the anti-doping list. The forward-leaning note — the July 2026 PCAC evaluation [16] — sits alongside these present-tense facts, not in place of them.